Pharma stocks were up after the President went easy on drugmakers.
Jay Appel is executive director of Bristol-Myers Squibb.
Heather Bell is SVP, global head of digital and analytics of Sanofi.
Ryan Billings is the senior director, digital innovation at Amag Pharmaceuticals.
Ozgun Demir is the director, digital strategy at Novartis.
Dr. Jessica Grossman is CEO of Medicines360.
Grant Groves is global customer innovation lab, U.S. lead at Boehringer Ingelheim.
Kishore Kumar is head of oncology innovation and integration at AstraZeneca.
Laurie Myers is global health literacy director of Merck.
Doug Noland is head, patient experience at Astellas.
Sandra Shpilberg is founder and CEO of Seeker Health.
Justin Chase is EVP and head, innovation and media at Intouch Solutions.
Susan Dorfman is chief commercial officer of CMI/Compas.
Dan Renick is president of Precision Value & Health.
Pharma companies are likely to put up aggressive resistance to the measure, introduced earlier this month.
The pharmaceutical company is undergoing a global restructuring as it relaunches its brand in the U.S. and Canada.
PhRMA wants to clear the air about drug pricing with the consumer-focused extension of the Let's Talk About Cost campaign.
Clayman says the company's next 18 months are all about Zilretta, with further pipeline construction next up.
The divisional VP and head of public affairs has seen it all, including the transformation from a traditional comms organization to a more dynamic and content-led group.
When you've figured out the difference, people will walk through fire for you, a mentor once told her.
Technology executives discussed how pharma companies can leverage social media to better engage with patients online.
PhRMA hires Ubl as CEO; two drugs report superior results in kidney-cancer trials compared to the standard of care; Novo Nordisk's shares rise on Tresiba approval
Craig Rothenberg joined Turing as its first comms chief less than two months ago.
Purdue Pharma launched a new resource around the abuse-deterrent properties of some of its painkillers.
Allergan executives attributed strong sales of branded products to recent investments in direct-to-consumer advertising.
AstraZeneca signs two immuno-oncology collaboration deals; UK cost watchdog goes after Pfizer over epilepsy medication price tag; Boston Globe reports drugmakers are funneling more money through CME programs
Eylea's robust second quarter of sales can be attributed in part to its ability to erase market share of competitors.
The PBM said AstraZeneca's diabetes medications Onglyza and Kombiglyze XR will not be covered next year.
Shire buys Foresight Biotherapeutics for $300 million; Novartis sold off three investigational drugs into Mereo BioPharma; new blood thinners linked to 8,000 deaths since 2010
Test your knowledge in this week's edition of the MM&M Weekly News Quiz.